Navigation Links
Cancer risk among nuclear industry workers

A cohort multinational study was done involving 598 068 nuclear industry workers from 15 countries.// The study was done to estimate the risk of cancer after administrating low doses of radiation.

This study is an international collaborative study to estimate the cancer risk among radiation workers in the nuclear industry to find out the risk of cancer occurrence after low dose exposure of radiation.

The study recruits were employed in 154 different facilities, involved in nuclear power production, research, waste management and industries of fuel, isotope and weapon. During the study period, about 24,158 (5.9%) of recruits died, 6519 from cancer other than leukaemia and 196 from leukaemia (excluding lymphocytic leukaemia).

Results from the study show that there is an increased risk of cancer exists in the recruits even at a low dose and a significant increase risk for all cancers (excluding leukaemia). Some factors like smoking and diet in recruits can have an association between radiation dose and risk of cancer. Some earlier studies have found associations between radiation dose and smoking and while others have not. Factors such as smoking can confound the association between radiation doses and risk only if they are related both to risk of cancer and to dose.

Current recommendations form the International Commission on Radiological Protection (ICRP) are to limit occupational doses to 100 Sv (sieverts) over five years (not to exceed 50 Sv in any one year) and doses to the public to 1 Sv per year. This study results show that an exposure of 100 Sv will cause 9.7% mortality from cancer (excluding leukaemia), and a 5.9% increased mortality from cancers excluding leukaemia, lung, and pleura.

Our study is the largest study on nuclear industry workers conducted so far, and provides an estimation of radiation risk. These results suggest that there is an increased risk of cancer occurs even at a lower dose of nucle ar radiation.


'"/>




Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2017)... Tampa, Fla. (PRWEB) , ... June 24, 2017 ... ... Fla., is now offering genetic testing for medications in select Florida and Texas ... of pharmacogenomics. , This new application of genetic testing recognizes the role ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island ... Care Management Alerts and Dashboards, an innovative new service enabling healthcare providers to ... Care Management Alerts and Dashboards provide near real-time data about patients admitted to ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Military Officers Association of America (MOAA) announced ... Veterans Affairs, retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the ... an intimacy with the issues and challenges veterans face with the VA. Following a ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... The Aesthetic ... facelift . Dr. Talei has come up with a proprietary technique that he calls ... lifts tissues that have dropped. For all ages, patients can expect to look refreshed, ...
(Date:6/23/2017)... Santa Monica, CA (PRWEB) , ... June 23, 2017 , ... ... PureLife as the endorsed amalgam separator supplier for CDA members. As part of the ... a reduced price of $99, saving more than $400 off the retail value. This ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... ALTO, Calif. , June 9, 2017 ... device company focused on the design, manufacture, sale and ... the market on the progress of its commercial roll-out ... is now available in more than one hundred (100) ... AeroForm offers a needle-free alternative for ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
Breaking Medicine Technology: